Discover the Arthramid Difference

“Arthramid is a game changer for all equine athletes. It all starts in the synovium with synovitis and capsulitis, before we get to osteoarthritis. I routinely tell my horse owners, ‘save the synovium, save the joint’.” Dr. Dan Carter — Owner of Countryside Veterinary Hospital, Covington, GA

I manage horses that compete in a variety of disciplines and with the owner abilities ranging from novice to professional. As such, owner expectations vary markedly for managing the joint disease their horse may have. For example, cases of osteoarthritis typically seen can be early onset or be chronic in nature, and ranging from mild to severe. Patient age can be as young as 3 to over 20, and suffering from other disease processes such as endocrine issues. Managing client expectations is a challenge and an art. Finding the best solution for the client is the intended outcome and is not always easy to achieve.

Arthramid enables me to effectively manage joints that have mild, moderate or severe osteoarthritic changes for a prolonged period of time and with very little chance of having an adverse reaction, even in those patients with other disease processes occurring concurrently. This provides peace of mind for the owner and myself. It also works out to be financially viable in the long-term. Arthramid has been a great option for horse owners of all levels to provide effective osteoarthritis management.

The longevity of effect and owner perception of Arthramid not being a bioactive drug, are by far the biggest benefits. I would definitely recommend Arthramid.

I was one of the first vets to use Arthramid worldwide and have now used Arthramid for over 10 years in our clinic. We have injected over a thousand horses and have found it to be very safe. It has been a major game-changer in the way we treat OA in our patients. We have fantastic results with really frustrating cases and are still working on new indications and treatment schemes for the product. We are also looking into the ongoing research, especially around the Mode of Action.

There are not many “new” products implemented in our OA Toolbox in recent years. Regenerative medicine and Bisphosphonates were the greatest new assets and I rate Arthramid in the same league. 2.5% iPAAG gives us the chance to minimize corticosteroids and we have no threats of “doping positive” cases. As well, some horses, instead of being destroyed, are happily back in business. I would encourage every orthopaedic vet to try the product. They will love it, if their case selection is appropriate.

I use Arthramid to treat thoroughbreds, standardbreds and equestrian horses. 90% of my work is lameness identification and treatment. I have injected well over 600 joints with Arthramid and I have experienced no side affects.

I have used all the alternative joint treatments over the last 50 years and consider Arthramid with or without triamcinolone superior to all other treatments. 85 % of my thoroughbred lameness localises to the intercarpal joint. If we are treating early cases before severe bone changes have occurred we will achieve long term reduction of joint inflammation. I have been using it as prophylactic in some stables. If we have major bone changes I add triamcinolone as required. I have used Arthramid in Fetlocks, TMT, Coffin, Pastern and stifle joints. In the gliding joints it is a superb product with spectacular results. In my experience joint pain on flexion is gone in 2 weeks and usually lameness markedly reduced but the maximum result is not achieved for 6 weeks. In summary Arthramid is a very valuable treatment option and is my first port of call for all lamenesses involving non septic joint inflammation

“It’s given me another tool in my arsenal to effectively manage all stages of equine osteoarthritis, especially those horses with equine metabolic disease.” Dr. Vern Dryden — Owner of Bur Oak Sports Medicine & Lameness, Lexington, KY

I see lame horses that I qualify as “non-responders”. The diagnosis/localisation of pain is accurate on those cases, but they do not respond to rest, and corticosteroids +/- HA intrasynovial. These represent my biggest challenge. Arthramid is often of great help on those cases in association with orthopaedic shoeing, magnetic diathermy and a revisited exercise program to regain and maintain soundness.

The second set of cases that represent a challenge are horses presented with poor performance. They are not genuinely lame, but several sites in their body including joints show signs of wear and tear. This accumulation of stress is associated with the athletic activity they perform and also to some individual predispositions to injury (poor conformation, overweight, lack of repair capacities). On these cases, Arthramid for its long duration of action can help.

The third group of horses I see as a challenge are diagnosed with soft tissue injuries within synovial structures (tendon sheath, bursa or joint). In general, the body responds poorly to healing those lesions. It is still unclear to me if Arthramid can help to return some of these horses to soundness when unsatisfactory healing of intrasynovial soft tissue has occurred.

Arthramid is a very potent and very safe drug to use, and I recommend it to my clients and other vets. Arthramid should be in the therapeutic toolbox of any equine veterinarian. I see Arthramid as a solution with great potential, and more work is needed to refine its use.

“Arthramid has transformed how I treat osteoarthritis. It’s easy to administer, highly effective, and has redefined my approach to post-op recovery and OA management.”

“Arthramid should be a go-to for earlier OA management in small animals. It’s safe, long-lasting, and supports healthier joints.”

I have utilised hundreds of doses of 2.5% iPAAG gel since 2014, and during this period I have learnt how to maximise its benefit in my caseload of predominantly Thoroughbred racehorses. In my opinion, it can minimise the use of intra-articular corticosteroids or other joint therapies used in Thoroughbred stables. 2.5% iPAAG is not a cortisone and shouldn’t be expected to diminish acute inflammation like corticosteroids do. In my opinion, it appears to have the greatest clinical effect in appropriately diagnosed joints with low-grade performance limiting lameness that are treated early in the horse’s preparation, or if utilised within a preparation given time (approximately 3 weeks) before one would expect to see a marked clinical improvement.

“We treated Sound (front fetlocks) in December 2019 which correlates with his turn around in form in February and March 2020, he was again treated in June 2020 (front fetlocks) and July 2020 (left front tendon sheath) after a flare of synovitis. Within 3 weeks both fetlocks and tendon sheath were tight and his action terrific. He went on to run 2nd in the Lexus and win the G2 Zipping Classic (5+ months after injection). As an 8yo stallion Sound tends to hold condition and to reach peak fitness he underwent a tough spring training campaign. On his non gallop days he would complete 4000m of cantering daily, this is a lot of miles on his joints and I do not believe we could have kept him sound without the use of Arthramid. Not only did he perform well but he maintained soundness and his action improved throughout the preparation.”

“Arthramid has become the most common product I reach for in joint treatments. I’ve found this product works best in active sport horses who are starting to lose the elasticity to their joints.”